Literature DB >> 24837325

Sample size requirements to detect a two- or three-way interaction in longitudinal cluster randomized clinical trials with second-level randomization.

Moonseong Heo1, Xiaonan Xue2, Mimi Y Kim2.   

Abstract

BACKGROUND: When randomizations are assigned at the cluster level for longitudinal cluster randomized trials (longitudinal-CRTs) with a continuous outcome, formulae for determining the required sample size to detect a two-way interaction effect between time and intervention are available.
PURPOSE: To show that (1) those same formulae can also be applied to longitudinal trials when randomizations are assigned at the subject level within clusters and (2) this property can be extended to 2-by-2 factorial longitudinal-CRTs with two treatments and different levels of randomization for which testing a three-way interaction between time and the two interventions is of primary interest.
METHODS: We show that slope estimates from different treatment arms are uncorrelated, regardless of whether randomization occurs at the third or second level and also regardless of whether slopes are considered fixed or random in the mixed-effects model for testing two-way or three-way interactions. Sample size formulae are extended to unbalanced designs. Simulation studies were applied to verify the findings.
RESULTS: Sample size formulae for testing two-way and three-way interactions in longitudinal-CRTs with second-level randomization are identical to those for trials with third-level randomization. In addition, the total number of observations required for testing a three-way interaction is demonstrated to be four times as large as that required for testing a two-way interaction, regardless of the level of randomization for both fixed- and random-slope models. LIMITATIONS: The findings may be only applicable to longitudinal-CRTs with normally distributed continuous outcome.
CONCLUSION: All of the findings are validated by simulation studies and enable the design of longitudinal clinical trials to be more flexible in regard to the level of randomization and allocation of clusters and subjects.
© The Author(s), 2014.

Entities:  

Year:  2014        PMID: 24837325      PMCID: PMC4233204          DOI: 10.1177/1740774514532724

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  6 in total

1.  Statistical power and optimal design for multisite randomized trials.

Authors:  S W Raudenbush; X Liu
Journal:  Psychol Methods       Date:  2000-06

2.  Sample sizes required to detect two-way and three-way interactions involving slope differences in mixed-effects linear models.

Authors:  Moonseong Heo; Andrew C Leon
Journal:  J Biopharm Stat       Date:  2010-07       Impact factor: 1.051

3.  Remission in depressed geriatric primary care patients: a report from the PROSPECT study.

Authors:  George S Alexopoulos; Ira R Katz; Martha L Bruce; Moonseong Heo; Thomas Ten Have; Patrick Raue; Hillary R Bogner; Herbert C Schulberg; Benoit H Mulsant; Charles F Reynolds
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

4.  Sample size requirements to detect an intervention by time interaction in longitudinal cluster randomized clinical trials with random slopes.

Authors:  Moonseong Heo; Xiaonan Xue; Mimi Y Kim
Journal:  Comput Stat Data Anal       Date:  2013-04-01       Impact factor: 1.681

5.  Sample Sizes Required to Detect Interactions between Two Binary Fixed-Effects in a Mixed-Effects Linear Regression Model.

Authors:  Andrew C Leon; Moonseong Heo
Journal:  Comput Stat Data Anal       Date:  2009-01-15       Impact factor: 1.681

6.  Sample size requirements to detect an intervention by time interaction in longitudinal cluster randomized clinical trials.

Authors:  Moonseong Heo; Andrew C Leon
Journal:  Stat Med       Date:  2009-03-15       Impact factor: 2.373

  6 in total
  1 in total

1.  Generalized SAMPLE SIZE Determination Formulas for Investigating Contextual Effects by a Three-Level Random Intercept Model.

Authors:  Satoshi Usami
Journal:  Psychometrika       Date:  2016-11-01       Impact factor: 2.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.